SH2D1A: A Potential Drug Target and Biomarker (G4068)

Target Name: SH2D1A

NCBI ID: G4068

SH2D1A

SH2D1A: A Potential Drug Target and Biomarker

SH2D1A, also known as SH2D1A protein (isoform 2), is a protein that is expressed in various tissues and cells throughout the body. It is a member of the SH2D family of proteins, which are known for their role in intracellular signaling. In particular , SH2D1A is involved in the regulation of cell adhesion, and it is thought to play a key role in the development and maintenance of tight junctions, which are a type of cell-cell adhesion that is essential for tissue structure and function.

In recent years, researchers have been interested in investigating the potential drug targets and biomarkers for SH2D1A. This is because the protein has been shown to play a role in the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition , SH2D1A has also been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of tissues and organs, such as the development of tissues and organs during development and the regulation of cell growth and differentiation.

One potential mechanism by which SH2D1A could be targeted as a drug is through its role in the regulation of cell adhesion. SH2D1A is known to be involved in the formation of tight junctions, which are critical for the development and maintenance of tissues and organs. tight junctions are specialized junctions that are found in the intercellular space and allow cells to exchange nutrients, waste products, and other substances. They are formed by a complex of proteins that include SH2D1A, and they are thought to be involved in the regulation of the movement of cells through the space.

Research has shown that SH2D1A is involved in the regulation of tight junction formation and the maintenance of tight junctions. This is thought to be important for the development and maintenance of tissues and organs, as tight junctions are critical for the proper functioning of these structures. For example, tight junctions help to maintain the integrity of tissues and organs, as they help to prevent cells from coming into contact with each other and exchanging substances. In addition, tight junctions are also important for the regulation of ion and solute transport, as well as the regulation of cell signaling pathways.

Another potential mechanism by which SH2D1A could be targeted as a drug is through its role in the regulation of cell growth and differentiation. SH2D1A is known to be involved in the regulation of cell growth and differentiation, and it is thought to play a key role in the development and maintenance of tissues and organs. This is because SH2D1A is involved in the regulation of the formation of cells that are derived from a single cell, as well as the regulation of the growth and differentiation of cells that have already been formed.

Research has shown that SH2D1A is involved in the regulation of cell growth and differentiation. This is thought to be important for the development and maintenance of tissues and organs, as the regulation of cell growth and differentiation is critical for the formation and maintenance of these structures . In addition, SH2D1A is also thought to be involved in the regulation of cell apoptosis, which is the process by which cells die and are removed from the body. This is important for the development and maintenance of tissues and organs, as it helps to remove damaged or dysfunctional cells.

Another potential mechanism by which SH2D1A could be targeted as a drug is through its role in the regulation of cellular signaling pathways. SH2D1A is known to be involved in the regulation of cellular signaling pathways, and it is thought to play a key role in the development and maintenance of tissues and organs. This is because SH2D1A is involved in the regulation of the movement of cells through the

Protein Name: SH2 Domain Containing 1A

Functions: Cytoplasmic adapter regulating receptors of the signaling lymphocytic activation molecule (SLAM) family such as SLAMF1, CD244, LY9, CD84, SLAMF6 and SLAMF7. In SLAM signaling seems to cooperate with SH2D1B/EAT-2. Initially it has been proposed that association with SLAMF1 prevents SLAMF1 binding to inhibitory effectors including INPP5D/SHIP1 and PTPN11/SHP-2 (PubMed:11806999). However, by simultaneous interactions, recruits FYN which subsequently phosphorylates and activates SLAMF1 (PubMed:12458214). Positively regulates CD244/2B4- and CD84-mediated natural killer (NK) cell functions. Can also promote CD48-, SLAMF6 -, LY9-, and SLAMF7-mediated NK cell activation. In the context of NK cell-mediated cytotoxicity enhances conjugate formation with target cells (By similarity). May also regulate the activity of the neurotrophin receptors NTRK1, NTRK2 and NTRK3

The "SH2D1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH2D1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets